Equity Profile

NVO

Novo Nordisk A/S

Health CarePharmaceuticals$217.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novo Nordisk A/S is a leading global healthcare company focused on diabetes care and hormone replacement therapies. With a market cap of $218 billion, it plays a significant role in the pharmaceutical industry, particularly as the demand for diabetes treatments continues to grow amid rising global health concerns.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well Novo Nordisk is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate how effectively the company is expanding its market share and meeting demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, surpassing expectations by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Continue to innovate in diabetes care and hormone therapy.
Focus on expanding market presence in emerging markets.
Maintain commitment to sustainable practices in production.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Novo Nordisk's upcoming earnings, especially following a strong performance last quarter.

Bull Case

If Novo Nordisk can demonstrate continued growth in its diabetes care segment and maintain or improve its EPS, it could see a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could face a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the sales figures for diabetes care products this quarter?

Sales data will be crucial in assessing the company's growth trajectory and market demand.

How does management plan to address any potential supply chain challenges?

Supply chain issues could impact production and sales, making this a key area for investor concern.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the growth potential in emerging markets where Novo Nordisk has been expanding aggressively.

Supporting Evidence

Recent trends show increased demand for diabetes treatments in developing regions.

Options pricing suggests expectations of high volatility, indicating uncertainty that may not align with actual growth.

Novo Nordisk's recent product launches could drive unexpected revenue growth.

Key Risk

If diabetes care sales exceed expectations significantly, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth in a competitive market.

Bull Confirmed If

Sales growth in diabetes care exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in diabetes care sales or a significant miss on EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests the stock could rise around 3.6% on the first day.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations, history suggests a potential decline of about 4.1% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on diabetes care sales performance.
2Management's strategy for addressing supply chain issues.
3Any new product launches or innovations in the pipeline.
4Insights into market expansion efforts in emerging markets.
5Guidance on future earnings expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well Novo Nordisk is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate how effectively the company is expanding its market share and meeting demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1 2026, Novo Nordisk reported an EPS of $1.04, surpassing expectations by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Continue to innovate in diabetes care and hormone therapy.
Focus on expanding market presence in emerging markets.
Maintain commitment to sustainable practices in production.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Novo Nordisk's upcoming earnings, especially following a strong performance last quarter.

Bull Case

If Novo Nordisk can demonstrate continued growth in its diabetes care segment and maintain or improve its EPS, it could see a strong positive reaction from the market.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could face a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the sales figures for diabetes care products this quarter?

Sales data will be crucial in assessing the company's growth trajectory and market demand.

How does management plan to address any potential supply chain challenges?

Supply chain issues could impact production and sales, making this a key area for investor concern.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the growth potential in emerging markets where Novo Nordisk has been expanding aggressively.

Supporting Evidence

Recent trends show increased demand for diabetes treatments in developing regions.

Options pricing suggests expectations of high volatility, indicating uncertainty that may not align with actual growth.

Novo Nordisk's recent product launches could drive unexpected revenue growth.

Key Risk

If diabetes care sales exceed expectations significantly, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth in a competitive market.

Bull Confirmed If

Sales growth in diabetes care exceeding 10% year-over-year would confirm the bull case.

Bear Confirmed If

A decline in diabetes care sales or a significant miss on EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests the stock could rise around 3.6% on the first day.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may experience a muted reaction.

Miss

If the company misses expectations, history suggests a potential decline of about 4.1% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on diabetes care sales performance.
2Management's strategy for addressing supply chain issues.
3Any new product launches or innovations in the pipeline.
4Insights into market expansion efforts in emerging markets.
5Guidance on future earnings expectations.